Cybin Corp. Potentially Poised to be First Company Bringing Psychedelic Medicine to Treat Major Depressive Disorder

• Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD
• Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need
• With secured delivery mechanisms and manufacturing contract in hand, Cybin appears well positioned to capitalize on growing market trend

As big pharma has failed to bring groundbreaking drug innovations into the mental health space, new data increasingly shows that psychedelics may close this gap, creating an entirely new market of safe and effective psychedelics medicines (http://nnw.fm/ZaMw1). Cybin Corp., a leading Canada-based, life-sciences company, is focused on developing pharmaceutical-grade psychedelic products and appears ideally positioned to make the most of this groundbreaking research.

Found in certain species of mushrooms, psilocybin — the main compound of pharmaceutical psychedelic products — has shown positive results for the treatment of anxiety, depression, PTSD, addiction, eating disorders and ADHD. As a research-first, life-science company, Cybin views mushroom-derived psychedelic compounds as brain boosters that have the potential to rebuild pathways and break negative patterns.

Psilocybin offers a scientific breakthrough in treating these conditions as it is rapidly metabolized to psilocin, which impacts serotonin receptors in the brain. With an increasing number of scientific research and clinical studies documenting that this naturally occurring, nonhabit-forming, psychedelic compound offers considerable positive effects in the treatment of mental health and other conditions, the serotonergic psychedelics today are being increasingly viewed in a new light as society embraces these benefits. Leading the wave of the mushroom-based products revival, Cybin has been laying the foundation for the moment pharmaceutical psychedelics achieve recognition in North America and worldwide.

Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in the Caribbean, Cybin has already filled a patent application for a diverse set of delivery mechanisms, identified synthetic psilocybin active pharmaceutical ingredients (“API”) sources and obtained a contract with a synthetic psilocybin oral film manufacturer.

It currently takes researchers around 12 months to get psilocybin for their studies as they wait for regulatory approval. In contrast, Cybin has secured 25mg API available immediately, which is sufficient for Phase 2a and Phase 2b trials in patients with moderate depressive disorder. The company is also in the process of developing its own proprietary API for psychedelic clinical research, with an initial focus on psilocybin and with a view of expanding to other analogs found in mushrooms (http://nnw.fm/Il9X5).

Cybin operates in the functional mushroom market with a goal to develop fungi-derived psychedelic and medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focused on advancing research and development of psilocybin-based psychedelic pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products.

According to the World Health Organization, more than 700 million individuals around the world are affected by some type of mental illness, addiction, or eating disorder. Clearly, there is a considerable unmet medical need for effective treatments for these types of mental health conditions. Led by a proven team of professionals with extensive experience in clinical trials and commercialization of new drugs, Cybin is emerging as a leader in the psychedelics space, poised to leverage its robust scientific capabilities to capitalize on the significant psychedelics-growth potential.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.